BerGenBio
Clinical-stage biopharma that developed selective AXL kinase inhibitors for cancer.
BGBIO | OL
Overview
Corporate Details
- ISIN(s):
- NO0012921180 (+2 more)
- LEI:
- 213800TYYFXKYF3V2A23
- Country:
- Norway
- Address:
- MØLLENDALSBAKKEN 9, 5009 BERGEN
- Website:
- https://www.bergenbio.com/
- Sector:
- Manufacturing
Description
BerGenBio was a clinical-stage biopharmaceutical company focused on developing first-in-class selective AXL kinase inhibitors. The company's therapeutic candidates targeted AXL as a potential cornerstone of therapy for aggressive, advanced, and treatment-resistant cancers. In October 2025, BerGenBio completed a merger with Oncoinvent ASA, and the combined entity was renamed Oncoinvent.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2018-01-29 07:00 |
BerGenBio: Encouraging I-O clinical data with selective AXL inhibitor bemcentin…
|
English | 63.3 KB | ||
| 2018-01-29 07:00 |
BerGenBio: Encouraging I-O clinical data with selective AXL inhibitor bemcentin…
|
English | 12.9 KB | ||
| 2018-01-09 07:00 |
BerGenBio meets first efficacy endpoint in phase II trial with selective AXL in…
|
English | 51.8 KB | ||
| 2018-01-09 07:00 |
BerGenBio meets first efficacy endpoint in phase II trial with selective AXL in…
|
English | 10.2 KB | ||
| 2018-01-08 07:00 |
BerGenBio to present at Biotech Showcase 2018
|
English | 50.8 KB | ||
| 2018-01-08 07:00 |
BerGenBio to present at Biotech Showcase 2018
|
English | 4.8 KB | ||
| 2017-12-21 10:13 |
Financial calendar
|
English | 735 bytes | ||
| 2017-12-14 10:22 |
BerGenBio ASA: Share capital increase
|
Norwegian | 43.7 KB | ||
| 2017-12-14 10:22 |
BerGenBio ASA: Share capital increase
|
English | 1.9 KB | ||
| 2017-12-14 06:00 |
BerGenBio to present recent highlights from its clinical trials with selective …
|
English | 49.5 KB | ||
| 2017-12-14 06:00 |
BerGenBio to present recent highlights from its clinical trials with selective …
|
English | 2.9 MB | ||
| 2017-12-14 06:00 |
BerGenBio to present recent highlights from its clinical trials with selective …
|
English | 7.8 KB | ||
| 2017-12-11 06:00 |
BerGenBio Presents Update on Ph II Clinical Trial with Selective AXL Inhibitor …
|
English | 88.9 KB | ||
| 2017-12-11 06:00 |
BerGenBio Presents Update on Ph II Clinical Trial with Selective AXL Inhibitor …
|
English | 8.6 KB | ||
| 2017-11-27 07:45 |
BerGenBio - US Clinical Trial Update
|
English | 28.8 KB |
Automate Your Workflow. Get a real-time feed of all BerGenBio filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for BerGenBio
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for BerGenBio via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
